Medication info
BILDAPORTMET 50/500 mg (Vildagliptin, Metformin Hydrochloride)

BILDAPORTMET 50/500 mg (Vildagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
GENEWON SCIENCE Co., Ltd.
Appearance
Light yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202301805 · Approved 2023.06.12 · Insurance code 671707320

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg daily are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients switching from combination therapy with vildagliptin and metformin: Patients switching to this medicine from combination therapy with vildagliptin and metformin may start at their current doses of vildagliptin and metformin. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment with this medicine.

Ingredients

Manufacturer
GENEWON SCIENCE Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in controlling blood sugar levels in patients with type 2 diabetes, in conjunction with dietary and exercise therapy. The combination of vildagliptin and metformin allows for effective management of blood sugar.

How to take

Adult dose

For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding vildagliptin 100mg and metformin 2000mg. Doses of vildagliptin greater than 100mg daily are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased up to 1 tablet of 50/1000mg twice daily. 2. Patients switching from combination therapy with vildagliptin and metformin: Patients switching to this medicine from combination therapy with vildagliptin and metformin may start at their current doses of vildagliptin and metformin. No studies have been conducted to evaluate the safety and efficacy of switching to this medicine from another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment with this medicine.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia, so caution is necessary. It should not be used in patients with moderate to severe renal impairment or heart failure, and should be avoided in patients with renal impairment due to acute heart disease or sepsis. Before undergoing tests using iodine-based radiographic contrast agents, this medication should be discontinued at least 48 hours prior and resumed only after confirming normal kidney function. It is not to be used in patients with hypersensitivity to this drug, or in those with type 1 diabetes or diabetic ketoacidosis. Caution is also advised for patients with severe infections, severe trauma, malnutrition, liver dysfunction, and severe pulmonary dysfunction. Women who are pregnant or breastfeeding should not take this medication. Caution is required as irregular meals, excessive exercise, and interactions with other medications may increase the risk of hypoglycemia or lactic acidosis. During treatment, liver and kidney functions should be regularly monitored for abnormalities, and if liver function is severely impaired, the medication should be discontinued. If symptoms of lactic acidosis, such as respiratory distress, abdominal pain, muscle cramps, weakness, or hypothermia, occur, consult a doctor immediately. Alcohol consumption should be avoided while taking this medication, as it may increase the risk of lactic acidosis. If symptoms of hypoglycemia appear, take sugar immediately and consult a doctor if necessary. If surgery is planned, discontinue this medication 48 hours before the surgery and resume only after confirming normal kidney function post-surgery. Elderly patients are at higher risk of renal function decline, so dosage adjustments and regular kidney function monitoring are required. Patients taking this medication should notify their doctor of any sudden weight changes, dyspepsia, skin rash, or joint pain. This medication does not replace insulin therapy and should not be used in patients with type 1 diabetes. Certain occupations may involve a risk of accidents due to hypoglycemia or dizziness, requiring caution during use.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • hepatitis
  • abnormal liver function
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 33 more
  • nausea
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • weakness
  • hyperhidrosis
  • constipation
  • arthralgia
  • upper respiratory tract infection
  • nasopharyngitis
  • peripheral edema
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • taste disturbances
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal abnormalities
  • elevated serum amylase
  • increased lipolytic enzyme activity
  • vesicular pemphigoid

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be kept tightly sealed in its bottle. Additionally, it should be stored in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Light yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.